Neurotoxicity of Endogenous Cysteinylcatechols

Experimental Neurology

Volumn 148, Issue 1, 1997, Pages 26-33

  Montine, T J ^a   Picklo, M J ^a   Amarnath, V ^a   Whetsell Jr , W O ^a   Graham, D G ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; CATECHOL DERIVATIVE; CYSDOPAC; CYSTEINE; DOPAMINE; DRUG DERIVATIVE; GLUTAMATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYLASPARTIC ACID; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANIMAL; ARTICLE; BRAIN LEVEL; CELL CULTURE; CULTURE MEDIUM; DRUG ANTAGONISM; DRUG EFFECT; ELECTRON TRANSPORT; EMBRYONAL CARCINOMA; GLIA; HIPPOCAMPUS; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION REDUCTION REACTION; PARKINSON DISEASE; PATHOLOGY; PYRAMIDAL NERVE CELL; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; BRAIN CHEMISTRY; CARCINOMA, EMBRYONAL; CATECHOLS; CELLS, CULTURED; CULTURE MEDIA; CYSTEINE; DOPAMINE; ELECTRON TRANSPORT; EXCITATORY AMINO ACID ANTAGONISTS; HIPPOCAMPUS; MAGNETIC RESONANCE SPECTROSCOPY; N-METHYLASPARTATE; NAD(P)H DEHYDROGENASE (QUINONE); NEUROGLIA; OXIDATION-REDUCTION; PARKINSON DISEASE; PYRAMIDAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTORS, GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; TUMOR CELLS, CULTURED;

EID: 0031263929     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6662     Document Type: Article

References (35)

1. Cohen, G., and P. Werner. 1994. Free radicals, oxidative stress, and neurodegeneration. In Neurodegenerative Diseases (D. B. Calne, Ed.), pp. 139-162. Saunders, Philadelphia.
2. Reichmann, H., and P. Riederer. 1994. Mitochondrial disturbances in neurodegeneration. In Neurodegenerative Diseases (D. B. Calne, Ed.), pp. 195-204. Saunders, Philadelphia.
3. Schapira, A. H. V., V. M. Mann, J. M. Cooper, D. Krige, P. J. Jenner, and C. D. Marsden. 1992. Mitochondrial function in Parkinson's disease. Ann. Neurol. 32: S116-S124.
4. Graham, D. G. 1978. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol 14: 633-643.
5. Graham, D. G., S. M. Tiffany, W. R. Bell Jr., and W. F. Gutknecht. 1978. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol 14: 644-653.
6. Mann, D. M. A., and P. O. Yates. 1983. Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech. Ageing Dev. 21: 193-203.
7. Langston, J. W. 1988. Neuromelanin-containing neurons are selectively vulnerable in parkinsonism. TIPS 9: 347-348.
8. Ben-Shachar, D., and M. B. H. Youdim. 1990. Selectivity of melanized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction. J. Neural Transm. 29: 251-259.
9. Fornstedt, B., E. Rosengren, and A. Carlsson. 1986. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa, and dopac in the brains of eight mammalian species. Neuropharmacology 25: 451-454.
10. Fornstedt, B., E. Rosengren, and A. Carlsson. 1989. The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with degree of depigmentation of substantia nigra. J. Neural Transm. 1: 279-295.
11. Fornstedt, B., E. Pileblad, and A. Carlsson. 1990. In vivo autoxidation of dopamine in guinea pig striatum increases with age. J. Neurochem. 55: 655-659.
12. Beal, M. F. 1992. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31: 119-130.
13. Bowling, A. C., and M. F. Beal. 1994. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci. 56: 1151-1171.
14. Coyle, J. T., and P. Puttfarcken. 1993. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262: 689-695.
15. Greenamyre, J. T., and C. F. O'Brien. 1991. N-Methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch. Neurol. 48: 977-981.
16. Ito, S., T. Kato, and K. Fujita. 1988. Covalent binding of catechols to proteins through the sulfhydryl group. Biochem. Pharmacol. 37: 1707-1710.
17. Rosengren, E., E. Linder-Eliasson, and A. Carlsson. 1985. Detection of 5-S-cysteinyldopamine in human brain. J. Neural Trans. 63: 247-253.
18. Ito, S., S. Inoue, Y. Yamamoto, and K. Fujita. 1981. Synthesis and antitumor activity of cysteinyl-3,4-dihydroxyphenylalanines and related compounds. J. Med. Chem. 24: 673-677.
19. Montine, T. J., V. Amarnath, M. E. Martin, W. J. Strittmatter, and D. G. Graham. 1996. E-4-Hydroxy-2-nonenal is cytotoxic and crosslinks cytoskeletal proteins in P19 neuroglial cultures. Am. J. Pathol. 148: 89-93.
20. Whetsell, W. O., and Schwarz, R. 1983. In Excitotoxins (K. Fuxe and R. Schwarz, Eds.), pp. 207-219. Macmillan Press, London.
21. Ramsay, R. R., J. I. Salach, J. Dagar, and T. P. Singer. 1986. Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochem. Biophys. Res. Commun. 135: 269-275.
22. Ramsay, R. R., A. T. Kowal, M. K. Johnson, J. I. Salach, and T. P. Singer. 1987. The inhibition site of MPP+, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase. Arch. Biochem. Biophys. 259: 645-649.
23. Singer, T. P. 1976. Determination of the activity of succinate, NADH, choline, and glycerolphosphate dehydrogenases. In Methods in Biochemical Analysis (D. Glick, Ed.), Vol. 22, pp. 123-175. Wiley, New York.
24. 3H]glutamate suggests a mechanism of inactivation of an excitatory neuropeptide. J. Neurochem. 47: 1013-1019.
25. Lovinger, D. M., G. White, and F. F. Weight. 1989. Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science 243: 1721-1724.
26. Montine, T. J., T. M. Underbill, E. Linney and D. G. Graham. 1994. Fibroblasts that express aromatic amino acid decarboxylase have increased sensitivity to the synergistic cytotoxicity of L-dopa and manganese. Toxicol. Appl. Pharmacol. 128: 116-122.
27. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
28. Shen, X. M., B. Xia, M. Z. Wrona, and G. Dryhurst. 1996. Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: possible metabolites of relevance to Parkinson's disease. Chem. Res. Toxicol. 9: 1117-1126.
29. Shen, X. M., and G. Dryhurst. 1996. Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: Reaction pathways of potential relevance to Parkinson's disease. Chem. Res. Toxicol. 9: 751-763.
30. Montine, T. J., D. Y. Huang, W M. Valentine, V. Amarnath, A. Saunders, K. H. Weisgraber, D. G. Graham, and W. J. Strittmatter. 1996. Crosslinking of apolipoprotein E by products of lipid peroxidation. J. Neuropathol. Exp. Neurol. 55: 202-210.
31. Przedborski, S., V. Jackson-Lewis, U. Muthane, H. Jiang, M. Ferreira, A. B. Naini, and S. Fahn. 1993. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Neurology 34: 715-723.
32. Ben-Shachar, D., R. Zuk, and Y. Glinka. 1995. Dopamine neurotoxicity: Inhibition of mitochondrial respiration. J. Neurochem. 64: 718-723.
33. Ramsay, R. R., S. K. Youngster, W. J. Nicklas, K. A. McKeown, Y. Z. Jin, R. E. Heikkila, and T. P. Singer. 1989. Structural dependence of the inhibition of mitochondrial respiration and of NADH oxidase by 1-methyl-4-phenylpyridinium (MPP+) analogs and their energized accumulation by mitochondria. Proc. Natl. Acad. Sci. USA 86: 9168-9172.
34. Fornstedt, B., and A. Carlsson. 1991. Effects of inhibition of monoamine oxidase on the levels of 5-S-cysteinyl adducts of catechols in dopaminergic regions of the brain of the guinea pig. Neuropharmacology 30: 463-468.
35. Hastings, T. G., D. A. Lewis, and M. J. Zigmond. 1996. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. USA 93: 1956-1961.